Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.

Peuvrel L, Bachmeyer C, Reguiai Z, Bachet JB, André T, Bensadoun RJ, Bouché O, Ychou M, Dréno B.

Support Care Cancer. 2012 May;20(5):909-21. doi: 10.1007/s00520-012-1404-0. Epub 2012 Feb 24. Review.

PMID:
22361824
2.

[New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].

Ehmann LM, Heinemann V, Wollenberg A.

Internist (Berl). 2011 Nov;52(11):1359-64. doi: 10.1007/s00108-011-2896-2. German.

PMID:
21796420
3.

[Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects].

Gerber PA, Buhren BA, Kürle S, Homey B.

Hautarzt. 2010 Aug;61(8):654-61. doi: 10.1007/s00105-010-1943-6. Review. German.

PMID:
20628713
4.

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A.

Support Care Cancer. 2010 Apr;18(4):509-22. doi: 10.1007/s00520-009-0744-x. Epub 2010 Feb 10.

PMID:
20145956
5.

Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm.

Reguiai Z, Bachet JB, Bachmeyer C, Peuvrel L, Beylot-Barry M, Bezier M, Boucher E, Chevelle C, Colin P, Guimbaud R, Mineur L, Richard MA, Artru P, Dufour P, Gornet JM, Samalin E, Bensadoun RJ, Ychou M, André T, Dreno B, Bouché O.

Support Care Cancer. 2012 Jul;20(7):1395-404. doi: 10.1007/s00520-012-1451-6. Epub 2012 Apr 27. Review.

PMID:
22539049
6.

Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling?

Rodeck U.

J Cell Physiol. 2009 Jan;218(1):32-4. doi: 10.1002/jcp.21585. Review.

PMID:
18781585
7.

Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.

Štulhofer Buzina D, Martinac I, Ledić Drvar D, Čeović R, Bilić I, Marinović B.

Acta Dermatovenerol Croat. 2016 Apr;24(1):70-2.

PMID:
27149134
8.

Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.

Ocvirk J, Cencelj S.

J Eur Acad Dermatol Venereol. 2010 Apr;24(4):453-9. doi: 10.1111/j.1468-3083.2009.03446.x. Epub 2009 Sep 27.

PMID:
19793151
9.

Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.

Fischer A, Rosen AC, Ensslin CJ, Wu S, Lacouture ME.

Dermatol Ther. 2013 Mar-Apr;26(2):135-48. doi: 10.1111/dth.12027. Review.

PMID:
23551370
10.

Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.

Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C.

Br J Dermatol. 2009 Sep;161(3):515-21. doi: 10.1111/j.1365-2133.2009.09214.x. Epub 2009 Apr 10.

PMID:
19466958
11.

Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.

Fabbrocini G, Panariello L, Cacciapuoti S, Bianca D, Ayala F.

Dermatitis. 2012 Sep-Oct;23(5):237-8.

PMID:
23010833
12.

Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.

Wu PA, Balagula Y, Lacouture ME, Anadkat MJ.

Curr Opin Oncol. 2011 Jul;23(4):343-51. doi: 10.1097/CCO.0b013e3283474063. Review.

PMID:
21537180
13.

[Skin signs associated with epidermal growth factor inhibitors].

Hannoud S, Rixe O, Bloch J, Le Pelletier F, Lebrun-Vignes B, Doarika A, Khayat D, Chosidow O.

Ann Dermatol Venereol. 2006 Mar;133(3):239-42. French.

PMID:
16800173
14.

Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.

Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A.

J Am Acad Dermatol. 2015 Feb;72(2):203-18; quiz 219-20. doi: 10.1016/j.jaad.2014.07.032. Review.

PMID:
25592338
15.

Cutaneous reactions to epidermal growth factor receptor inhibitors.

Pomerantz RG, Mirvish ED, Geskin LJ.

J Drugs Dermatol. 2010 Oct;9(10):1229-34. Review.

PMID:
20941947
16.

[Cutaneous side effects of EGF receptor inhibitors].

Nassar D, Soutou B, Aractingi S.

Bull Cancer. 2009 Dec;96 Suppl:S85-91. doi: 10.1684/bdc.2009.1000. French.

PMID:
20034874
17.

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.

Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, Maughan T, Morere JF, Santoro A, Sobrero A, Van Cutsem E, Layton A.

J Dtsch Dermatol Ges. 2005 Aug;3(8):599-606. Review.

PMID:
16033478
18.

[Cutaneous side effects of EGFR inhibitors--appearance and management].

Wollenberg A, Kroth J, Hauschild A, Dirschka T.

Dtsch Med Wochenschr. 2010 Jan;135(4):149-54. doi: 10.1055/s-0029-1244831. Epub 2010 Jan 25. Review. German.

PMID:
20101558
19.

Clinical research of EGFR inhibitors and related dermatologic toxicities.

Perez-Soler R, Van Cutsem E.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):10-6.

PMID:
18154213
20.

Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.

Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC.

J Am Acad Dermatol. 2006 Oct;55(4):657-70. Review.

PMID:
17010747

Supplemental Content

Support Center